3 results
Approved WMOCompleted
Primary:The primary objective of this study is to evaluate the efficacy of LDX administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo over the course of 7 weeks. This study will enrol children and adolescents (6-17 years of…
Approved WMOWill not start
Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC
Approved WMOCompleted
1) To evaluate the safety and tolerability of MLT*s npMNAs2) To evaluate the pharmacokinetics of intradermal desmopressin administration via MLT*s npMNAs